Μεταστατικό καρκίνωμα μαστού. Γραπτή επιστημονική ανακοίνωση στο 7ο Ελληνικό Συνέδριο Ογκολογίας

Title

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR HR+/HER2-METASTATIC BREAST CANCER: INSIGHTS FROM A GREEK REGISTRY STUDY BY THE HELLENIC SOCIETY OF MEDICAL ONCOLOGY

Written by

Boutis A., Agelaki S., ArdavanisA., Mavroudis D., Timotheadou E., Athanasiadis I., KotteasE., BobolakiI., Floros T., KarageorgopoulouS., AravantinosG., Tsoukalas N., SamelisG., TzovarasA., DimitriadouA., MatsiakouF., Nikolaou M., Katsika L., Mala A., Chatzifoti N., Boukovinas I., Saridaki Z.
On behalf of the Hellenic Society of Medical Oncology (HeSMO), Athens, Greece

Conclusions

– Hormonotherapy emerged as the main therapeutic approach for HR+/HER2- MBC in Greece, aligning with international trends. CDK4/6 inhibitors played a prominent role in both first and second-line settings.
– The study is a collection of real-world data about therapeutic strategy in patients with metastatic ER+/HER2- breast cancer between Greek oncologists, suggesting positive patient outcomes in the Greek population.
– These findings contribute valuable insights to opportunities for incorporation of novel therapies and/or clinical trials in Greece.

Δείτε την ανακοίνωση πατώντας εδώ

Μεταστατικό καρκίνωμα μαστού. Γραπτή επιστημονική ανακοίνωση στο 7ο Ελληνικό Συνέδριο Ογκολογίας